# Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Source: https://onco.cc/trials/nct04589845/  
OnCo record `nct04589845` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine and Inavolisib in advanced solid tumours, run by Hoffmann-La Roche, active and no longer recruiting.

## Summary

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study is a phase 2 interventional study registered as NCT04589845 by Hoffmann-La Roche, with 920 participants enrolled, started 2021-01-18 and due to reach its primary completion in 2032-09-25. Interventions recorded: Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine and Inavolisib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04589845
- Phase: 2
- Setting: Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
- Sponsor: Hoffmann-La Roche
- Enrolled: 920

## Sources

- ClinicalTrials.gov NCT04589845: https://clinicaltrials.gov/study/NCT04589845

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Alectinib](https://onco.cc/drugs/alectinib/), [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Camonsertib](https://onco.cc/drugs/camonsertib/), [Entrectinib](https://onco.cc/drugs/entrectinib/), [Inavolisib](https://onco.cc/drugs/inavolisib/), [Ipatasertib](https://onco.cc/drugs/ipatasertib/), [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)

---
JSON: https://onco.cc/api/v1/entities/nct04589845.json